Invega sustenna e exclusividade de mercado

Os médicos psiquiatras já começaram a empurrar a injeção invega de 3 meses para cumprir o plano de mercado da Janssen pois a exclusividade de mercado acaba em dezembro de 2020, o que possibilita entrar similares no mercado e diminuir o preço devido a competição no mercado.

1. Generic Drugs
2. Invega Sustenna

Print Share

Generic Invega Sustenna Availability

See also: Generic Invega, Generic Invega Trinza
Invega Sustenna is a brand name of paliperidone, approved by the FDA in the following formulation(s):

INVEGA SUSTENNA (paliperidone palmitate - suspension, extended release;intramuscular)

• Manufacturer: JANSSEN PHARMS
  Approval date: July 31, 2009
  Strength(s): 39MG/0.25ML (39MG/0.25ML) ^[RLD], 78MG/0.5ML (78MG/0.5ML) ^[RLD], 117MG/0.75ML (117MG/0.75ML) ^[RLD], 156MG/ML (156MG/ML) ^[RLD], 234MG/1.5ML (156MG/ML) ^[RLD]

Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
December 20, 2020

https://www.drugs.com/availability/generic-invega-sustenna.html